FLT3 and acute myeloid leukemia: Compared with KMT2DWT AML, KMT2DMUT patients were more likely to co‐occur with FLT3 (52.0% vs. 28.1%, p = .016) and NPM1 (44.0% vs. 19.2%, p = .004) mutations (Figure 1E,F).